Lu Kevin Hai-Ning, Michel Julius, Kilian Michael, Aslan Katrin, Qi Hao, Kehl Niklas, Jung Stefanie, Sanghvi Khwab, Lindner Katharina, Zhang Xin-Wen, Green Edward W, Poschke Isabel, Ratliff Miriam, Bunse Theresa, Sahm Felix, von Deimling Andreas, Wick Wolfgang, Platten Michael, Bunse Lukas
DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Pediatric Hematology and Oncology, Clinic of Pediatrics III, University Hospital Essen, Essen, Germany.
Neurooncol Adv. 2022 Aug 31;4(1):vdac140. doi: 10.1093/noajnl/vdac140. eCollection 2022 Jan-Dec.
Glioblastoma (GBM) is characterized by low numbers of glioma-infiltrating lymphocytes (GIL) with a dysfunctional phenotype. Whether this dysfunctional phenotype is fixed or can be reversed upon culturing is poorly understood. The aim of this study was to assess T cell receptor (TCR)-dynamics and -specificities as well as determinants of GIL expansion by sequencing-based technologies and functional assays to explore the use of GIL for cell therapy.
By means of flow cytometry, T cell functionality in GIL cultures was assessed from 9 GBM patients. TCR beta sequencing (TCRB-seq) was used for TCR repertoire profiling before and after expansion. Microarrays or RNA sequencing (RNA-seq) were performed from 6 micro-dissected GBM tissues and healthy brain RNA to assess the individual expression of GBM-associated antigens (GAA). GIL reactivity against predicted tumor-associated antigens (TAA) and patient-individual GAA was assessed by ELISpot assay. Combined single cell (sc)TCR-/RNA-seq and post-expansion TCRB-seq were used to evaluate transcriptional signatures that determine GIL expansion.
Human GIL regains cellular fitness upon expansion. Profound TCR dynamics were observed during expansion and only in one of six GIL cultures, reactivity against GAA was observed. Paired scTCR/RNA-seq and TCRB-seq revealed predictive transcriptional signatures that determine GIL expansion.
Profound TCR repertoire dynamics occur during GIL expansion. transcriptional T cell states determine expansion capacity in gliomas. Our observation has important implications for the use of GIL for cell therapy including genetic manipulation to maintain both antigen specificity and expansion capacity.
胶质母细胞瘤(GBM)的特征是胶质瘤浸润淋巴细胞(GIL)数量少且具有功能失调的表型。这种功能失调的表型是固定的还是在培养后可以逆转,目前了解甚少。本研究的目的是通过基于测序的技术和功能测定来评估T细胞受体(TCR)的动态变化和特异性以及GIL扩增的决定因素,以探索GIL在细胞治疗中的应用。
通过流式细胞术,评估了9例GBM患者GIL培养物中的T细胞功能。在扩增前后,使用TCRβ测序(TCRB-seq)对TCR库进行分析。对6个显微切割的GBM组织和健康脑RNA进行微阵列或RNA测序(RNA-seq),以评估GBM相关抗原(GAA)的个体表达。通过ELISpot测定评估GIL对预测的肿瘤相关抗原(TAA)和患者个体GAA的反应性。联合单细胞(sc)TCR-/RNA-seq和扩增后TCRB-seq用于评估决定GIL扩增的转录特征。
人GIL在扩增后恢复细胞适应性。在扩增过程中观察到显著的TCR动态变化,并且仅在6个GIL培养物中的1个中观察到对GAA的反应性。配对的scTCR/RNA-seq和TCRB-seq揭示了决定GIL扩增的预测性转录特征。
在GIL扩增过程中发生显著的TCR库动态变化。转录性T细胞状态决定了胶质瘤中的扩增能力。我们的观察结果对GIL在细胞治疗中的应用具有重要意义,包括基因操作以维持抗原特异性和扩增能力。